Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures and CNS disorders for both hospital and home settings.
Read more
Years of combined industry experience
SE is the second most common CNS emergency in the US
Patients safely treated using therapeutically relevant doses of ganaxolone
Potential treatment for status epilepticus and other rare epilepsies that have few or no treatment options